<DOC>
	<DOC>NCT00814736</DOC>
	<brief_summary>To investigate the safety and overall tolerability of co-administration two PDE5 inhibitors UK369,003 and sildenafil</brief_summary>
	<brief_title>A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Healthy male subjects between the ages of 40 and 55 years, inclusive Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight &gt;50 kg (110 lbs). Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Loss of vision in one eye due to nonarteritic ischemic optic neuropathy (NAION) regardless of whether or not this event was temporally associated with the use of a PDE5 inhibitor.</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>